Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://jackv801vlt2.sharebyblog.com/profile